NASDAQ:SLNOSoleno Therapeutics Stock Price, Forecast & News

Soleno Therapeutics' stock was trading at $2.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SLNO shares have decreased by 13.1% and is now trading at $2.18. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Soleno Therapeutics.

Soleno Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Soleno Therapeutics.

Soleno Therapeutics Inc (NASDAQ:SLNO) announced its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.07. View Soleno Therapeutics' earnings history.

Soleno Therapeutics's stock reverse split before market open on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

3 brokerages have issued 1 year target prices for Soleno Therapeutics' shares. Their forecasts range from $8.00 to $10.00. On average, they anticipate Soleno Therapeutics' share price to reach $9.33 in the next year. This suggests a possible upside of 328.1% from the stock's current price. View analysts' price targets for Soleno Therapeutics.

News headlines about SLNO stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Soleno Therapeutics earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Soleno Therapeutics.

Soleno Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 1,810,000 shares, an increase of 195.8% from the June 15th total of 612,000 shares. Based on an average daily volume of 642,000 shares, the short-interest ratio is currently 2.8 days. Approximately 7.0% of the shares of the company are short sold. View Soleno Therapeutics' Current Options Chain.

Some companies that are related to Soleno Therapeutics include TransMedics Group (TMDX), Viewray (VRAY), Stereotaxis (STXS), Semler Scientific (SMLR), Cutera (CUTR), BioSig Technologies (BSGM), Fonar (FONR), Edap Tms (EDAP), Fc Global Realty (FCRE), electroCore (ECOR), IRIDEX (IRIX), Second Sight Medical Products (EYES), Precision Optics (PEYE), CHF Solutions (CHFS) and Reshape Lifesciences (RSLS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include SCYNEXIS (SCYX), Anavex Life Sciences (AVXL), Molecular Templates (MTEM), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Opko Health (OPK), Sorrento Therapeutics (SRNE), Tetraphase Pharmaceuticals (TTPH), AVEO Pharmaceuticals (AVEO) and Dynavax Technologies (DVAX).

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SLNO stock can currently be purchased for approximately $2.18.

Soleno Therapeutics has a market capitalization of $97.47 million. The company earns $-30,770,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Soleno Therapeutics employs 9 workers across the globe.

The official website for Soleno Therapeutics is www.soleno.life.

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]